Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Biotech column IMAGE
Biotech

A biotech unicorn prepares for a public offering, banking on gene therapy

By Damian Garde

Brain map
Biotech

9 things to know about Alkermes and its controversial drug for treatment-resistant depression

By Adam Feuerstein

Biotech

Pfizer, Bain launch a startup to focus on nervous system diseases

By Jonathan Saltzman — Boston Globe

Squamous_carcinoma_lung_cytology
Adam's Take

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

By Adam Feuerstein

China lung cancer scan
Biotech

Is China ready for a revolution in cancer therapy? Progress may hinge on access and screening

By Rebecca Robbins

Prostate Cancer
Biotech

Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

By Adam Feuerstein

The Readout LOUD

LISTEN: Drug prices on TV, immortal blockbusters, and genetic privacy

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Brain map
Biotech

New chemical eyed in fight vs. Alzheimer’s

By Jonathan Saltzman — Boston Globe

Adam's Take

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

By Adam Feuerstein

In the Lab

How the Navy brought a once-derided scientist out of retirement — and into the virus-selling business

By Eric Boodman

Lessons Learned
Lessons Learned

Lessons Learned: Here’s why this Broad Institute exec is jumping to a biotech startup

By Kate Sheridan

The Readout LOUD

LISTEN: Fake friends at the FDA, cancer counter-narratives, and biotech’s bear turn

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Healthcare Unicorn
Biotech

Amid a market slump, biotech makes room for unicorns

By Damian Garde

Jungeun Lee
Biotech

In the red-hot race to fill biotech jobs, benefits abound

By Jonathan Saltzman — Boston Globe

Biotech

New data for Genentech’s MS drug shows benefit of early treatment

By Kate Sheridan

Business

U.S. crackdown on foreign investments could cool Asia’s desire for U.S. biotech

By Damian Garde

Acute Promyelocytic Leukemia
Biotech

Early blood cancer trial is shuttered, possibly dimming hopes for promising therapy

By Damian Garde

Fish oil pills on pink
Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

FDA Headquarters
Biotech

FDA approves Akcea rare disease drug with a black box warning

By Kate Sheridan

Nick Leschly - Bluebird Bio
Biotech

Surprise! Bluebird Bio’s beta thalassemia gene therapy is already under review in Europe

By Adam Feuerstein

The Readout LOUD

LISTEN: Nobel snubs, millennial founders, and a new kind of lightning round

By Rebecca Robbins and Megan Thielking

STAT SPOTLIGHT
Biotech

Startup Spotlight: This Cambridge biotech snagged a deal with Roche without ever making a pitch

By Kate Sheridan

Sarepta - Cambridge
Biotech

Hop, skip, jump. Sarepta’s Duchenne gene therapy delivers early muscle function improvements

By Adam Feuerstein

Biotech

New data shows Genentech’s potential competitor for Spinraza inching forward

By Kate Sheridan

Ginkgo Bioworks 02
Biotech

In the booming field of synthetic biology, a back-end business reinvents itself

By Rebecca Robbins

Stock Market
Biotech

The biotech scorecard for the fourth quarter: 12 make-or-break industry events to watch

By Adam Feuerstein and Damian Garde

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Lab tests
Biotech

Momenta lays off half of its employees, including key executives

By Jonathan Saltzman — Boston Globe

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy